Invivyd (NASDAQ:IVVD) Insider Robert Allen III Sells 20,679 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 20,679 shares of Invivyd stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $0.72, for a total value of $14,888.88. Following the completion of the sale, the insider directly owned 195,808 shares in the company, valued at approximately $140,981.76. The trade was a 9.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Stock Performance

NASDAQ IVVD opened at $0.87 on Wednesday. The company has a market capitalization of $255.75 million, a P/E ratio of -2.63 and a beta of 0.71. Invivyd, Inc. has a one year low of $0.48 and a one year high of $3.07. The stock has a 50 day moving average price of $0.77 and a 200-day moving average price of $1.23.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The business had revenue of $14.29 million during the quarter, compared to the consensus estimate of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. As a group, equities analysts predict that Invivyd, Inc. will post -0.52 EPS for the current fiscal year.

Invivyd News Summary

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Analyst Ratings Changes

IVVD has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. HC Wainwright restated a “buy” rating on shares of Invivyd in a research report on Tuesday. Finally, BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Investors Weigh In On Invivyd

Several hedge funds and other institutional investors have recently made changes to their positions in IVVD. Chicago Partners Investment Group LLC bought a new stake in shares of Invivyd in the 1st quarter worth about $25,000. Courier Capital LLC purchased a new position in shares of Invivyd during the 4th quarter worth about $25,000. Bronte Capital Management Pty Ltd. bought a new position in Invivyd during the 4th quarter valued at about $27,000. DRW Securities LLC bought a new position in Invivyd during the 4th quarter valued at about $27,000. Finally, ProShare Advisors LLC purchased a new stake in Invivyd in the 4th quarter worth about $30,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.